AZD 4992

Drug Profile

AZD 4992

Alternative Names: AZD4992

Latest Information Update: 17 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; Bayer Schering Pharma
  • Developer Bayer Schering Pharma
  • Class Antineoplastics
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 31 Jan 2008 AstraZeneca discontinues its involvement in the development of AZD 4992
  • 17 Dec 2007 Phase-I clinical trials in Breast cancer in Germany (unspecified route)
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top